Other safety alerts
|
| |
| Singapore: HSA Alerts Public to “OxyELITE Pro” – an Unregistered Medicinal Product Linked to Serious Liver Injuries |
| |
The Health Sciences Authority (HSA) is alerting members of the public to an unregistered medicinal product labelled as “OxyELITE Pro”, which has been linked to numerous cases of serious liver injuries in the United States (US) and one case in Hong Kong. “OxyELITE Pro” is a medicinal product not approved for sale by HSA. However, investigations by HSA have found that the product is being sold illegally through the Internet in Singapore and some members of the public may have purchased the product from overseas.
“OxyELITE Pro” is marketed overseas as a dietary supplement and as a fat burner to achieve rapid weight loss. It is labelled to contain herbal extracts. Preliminary laboratory tests conducted by HSA on the “OxyELITE Pro” capsules bought from an Internet seller have found the product to contain 1,3-dimethylamylamine (DMAA) and yohimbine which are potent western medicinal ingredients that are not allowed to be present in supplements sold locally. Health products containing such ingredients require registration as medicinal products and can cause serious adverse effects when consumed without medical supervision. Investigations are ongoing to detect other potentially undeclared ingredients which may have caused the liver injuries.
In view of the seriousness of the liver injuries possibly related to “OxyELITE Pro”, HSA strongly advises members of the public who are taking this product to stop consuming it immediately. As a range of products is available under the brand name of “OxyELITE Pro”, it cannot be confirmed which specific formulation may be responsible for the liver injuries. As a precautionary measure, consumers are advised to stop taking this range of products labelled “OxyELITE Pro”. Members of the public are also advised to consult a doctor as soon as possible if they are feeling unwell after taking “OxyELITE Pro”.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/publish/hsaportal/../hsa_alerts_public6.html
In Hong Kong, the above product is not a registered pharmaceutical product. Related news has been released by FDA and was posted on the Drug Office websites on 9 and 15 October 2013. A press release was issued to appeal the public not to buy or use oral product labeled as OxyELITE Pro on 9 October 2013.
Ends/ Saturday, October 19, 2013
Issued at HKT 12:00 |
| |
|
